Alterity Therapeutics to Present at MST Financial Webinar

Rhea-AI Summary

Alterity Therapeutics (NASDAQ: ATHE), a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced an upcoming investor webinar. The event, hosted by MST Financial, is scheduled for July 25, 2024, at 8:30 AM AEST (July 24, 2024, at 6:30 PM ET).

CEO David Stamler will present recent company developments, including interim data from the Phase 2 open-label study of ATH-434 (202). Investors and shareholders can register for the Zoom webcast and will have the opportunity to ask questions following the presentation.

This webinar provides a platform for Alterity to share its progress in developing disease-modifying treatments and engage with its investor community.

MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data for the Phase 2 open-label study of ATH-434 (202).

Details are listed below:

Webcast details

AUSTRALIA PARTICIPANTS:

	Date:		Thursday, 25 July 2024
	Time:		8:30 a.m. AEST (Sydney/Melbourne)

UNITED STATES PARTICIPANTS:

	Date:		Wednesday, 24 July 2024
	Time:		3:30 p.m. Pacific Time
			6:30 p.m. Eastern Time

Register for the Zoom webcast:

https://mstfinancial-au.zoom.us/webinar/register/WN_8zfACjD8TqO7SsMcAyxzkg

Registration is required and dial in details will be sent directly upon registration.

Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064

U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386

FAQ

When is Alterity Therapeutics (ATHE) hosting its investor webinar?

Alterity Therapeutics (ATHE) is hosting its investor webinar on July 25, 2024, at 8:30 AM AEST for Australian participants, and July 24, 2024, at 6:30 PM ET for US participants.

What will be discussed in Alterity Therapeutics' (ATHE) upcoming webinar?

CEO David Stamler will present recent company developments, including interim data from the Phase 2 open-label study of ATH-434 (202), Alterity's treatment for neurodegenerative diseases.

How can investors participate in Alterity Therapeutics' (ATHE) July 2024 webinar?

Investors can participate by registering for the Zoom webcast through the provided link. Registration is required, and dial-in details will be sent directly upon registration.

Will there be a Q&A session during Alterity Therapeutics' (ATHE) July 2024 webinar?

Yes, investors will have the opportunity to ask questions during the call, at the conclusion of the presentation.